[TimAlerts] TBRA Up 665%

[TimChallenge] CLCD already peaked at 20.34 p/m and is dropping although it may find support in the low 18's

[TimChallenge] CLCD announces achievement of both primary and key secondary endpoints in the samurai phase 3 pivotal trial of lasmiditan in migraine

[TimChallenge] CLCD Up 79.40%

[TimChallenge] $VRX Up 14.5%

[TimChallenge] $MFRM up 114%

[TimChallenge] $PRKR up 75%

[TimChallenge] $LVGAF up 26%

[TimChallenge] SMLR UP 110%

[TimChallenge] SMLR